Height and nigral neuron density in Parkinson’s disease
Objective: To investigate the possible relationship between height and the density of neurons in the substantia nigra pars compacta (SNc). Background: The dopaminergic system modulates…Gold and silver nanoparticle-based Localized Surface Plasmon Resonance Sensor (LSPR) for the detection of histidine as a potential biomarker in Parkinson’s Disease.
Objective: Previous literature has proven that histamine has a crucial role in the process of neuroinflammation in Parkinson's Disease (PD) . We can indirectly detect…TRPV4 Mutation related Parkinson’s Disease with Scapuloperoneal spinal muscular atrophy
Objective: Scapuloperoneal spinal muscular atrophy (SPSMA) is a rare autosomal dominant disease caused by transient receptor potential cation channel (TRPV4) gene, involving scapular and peroneal…Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction
Objective: To evaluate whether the 123I-FP-CIT striatal uptake differs in Parkinson’s disease (PD) drug-naïve patients with and without sexual dysfunction. Background: Sexual dysfunction is one…Disease progression characterized by motor performance, dopaminergic neurodegeneration and T cell infiltration in the transgenic hm2-α-SYN-39 mouse model of Parkinson´s disease
Objective: To study disease progression in the transgenic (tg) hm2-α-SYN-39 mouse model of Parkinson´s disease (PD) by assessment of motor performance, dopaminergic neurodegeneration and T…Probabilistic tractography study of the nigrostriatal pathway in Parkinson’s disease
Objective: To investigate changes in connectivity of the nigrostriatal and striatonigral pathways in PD and association with clinical symptoms. Background: Loss of dopaminergic neurons in…To compare early / late onset MSA from the PAN American MSA (PANMSA) database
Objective: Compare two different cohorts of patients with the same pathology differentiated by age of onset. Background: Multiple system atrophy (MSA) is a rare neurodegenerative…PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…Remote patient monitoring with a digital biomarker approach generates clinically distinctive and meaningful sensor feature data in Parkinson’s disease: Differential relationships with MDS-UPDRS-III, PDQ-39 and DaT-SPECT
Objective: To determine whether sensor features derived from remote smartphone testing in Parkinson’s disease (PD) predicted clinical, quality of life and biomarker measures collected in…Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up
Objective: To identify clinical characteristics, predictors and biomarkers of pain at baseline and after a two-year follow-up period in newly diagnosed drug-naïve Parkinson's Disease (PD)…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.